4.7 Article

Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals

Journal

SCIENTIFIC REPORTS
Volume 7, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/srep40354

Keywords

-

Funding

  1. Swedish Research Council [K2010-56X-20345-04-3, K2014-57X-22451-01-5]
  2. Swedish Physicians Against AIDS Research Foundation [Fob2013-0008, Fob2015-0012]
  3. Magnus Bergvalls foundation
  4. Karolinska Institutet
  5. Delaney AIDS Research Enterprise (DARE) [AI096109]
  6. UCSF/Gladstone Institute of Virology & Immunology CFAR [P30 AI027763]
  7. CFAR Network of Integrated Systems [R24 AI067039]

Ask authors/readers for more resources

HIV-specific CD8(+) T cells demonstrate an exhausted phenotype associated with increased expression of inhibitory receptors, decreased functional capacity, and a skewed transcriptional profile, which are only partially restored by antiretroviral treatment (ART). Expression levels of the inhibitory receptor, T cell immunoglobulin and ITIM domain (TIGIT), the co-stimulatory receptor CD226 and their ligand PVR are altered in viral infections and cancer. However, the extent to which the TIGIT/CD226/PVR-axis is affected by HIV-infection has not been characterized. Here, we report that TIGIT expression increased over time despite early initiation of ART. HIV-specific CD8(+) T cells were almost exclusively TIGIT(+), had an inverse expression of the transcription factors T-bet and Eomes and co-expressed PD-1, CD160 and 2B4. HIV-specific TIGIThi cells were negatively correlated with polyfunctionality and displayed a diminished expression of CD226. Furthermore, expression of PVR was increased on CD4(+) T cells, especially T follicular helper (Tfh) cells, in HIV-infected lymph nodes. These results depict a skewing of the TIGIT/CD226 axis from CD226 co-stimulation towards TIGIT-mediated inhibition of CD8(+) T cells, despite early ART. These findings highlight the importance of the TIGIT/CD226/PVR axis as an immune checkpoint barrier that could hinder future cure strategies requiring potent HIV-specific CD8(+) T cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available